Caxton Associates LLP Acquires Shares of 5,110 Edwards Lifesciences Corporation $EW

Key Points

• Caxton Associates LLP invested approximately $370,000 in Edwards Lifesciences Corporation by acquiring 5,110 shares in the 1st quarter.
• Analyst ratings for Edwards Lifesciences have generally been positive, with multiple firms including Citigroup and Deutsche Bank issuing “buy” ratings and increasing their target prices.
• Edwards Lifesciences reported better-than-expected fiscal results, with a revenue of $1.53 billion and an EPS of $0.67, surpassing analyst estimates.

Caxton Associates LLP acquired a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,110 shares of the medical research company's stock, valued at approximately $370,000.

A number of other institutional investors have also added to or reduced their stakes in EW. Nuveen LLC purchased a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $330,881,000. Jennison Associates LLC raised its stake in Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after buying an additional 2,576,383 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Edwards Lifesciences during the fourth quarter worth $92,631,000. AQR Capital Management LLC boosted its position in Edwards Lifesciences by 339.7% during the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company's stock valued at $65,381,000 after acquiring an additional 709,648 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in Edwards Lifesciences during the 4th quarter valued at $43,545,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on EW. Morgan Stanley upped their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. The Goldman Sachs Group reissued a "buy" rating on shares of Edwards Lifesciences in a research report on Friday, July 25th. Evercore ISI raised their price target on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a report on Friday, July 25th. Barclays boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Finally, JPMorgan Chase & Co. raised their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $86.26.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $1.47 during mid-day trading on Monday, reaching $76.10. 3,734,247 shares of the company traded hands, compared to its average volume of 3,779,818. The firm's fifty day moving average is $78.91 and its two-hundred day moving average is $75.48. The company has a market capitalization of $44.68 billion, a price-to-earnings ratio of 10.95, a price-to-earnings-growth ratio of 3.74 and a beta of 1.07. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.